Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
The Targeted Agent and Profiling Utilization Registry (TAPUR) study began recruiting its first patients last month. The trial, the first clinical trial undertaken by …
From - Diagnostic Testing & Emerging Technologies
While few direct-to-consumer (DTC) genetic testing consumers share their results with a health care provider, most who do are satisfied with the discussion of results…
From - Diagnostic Testing & Emerging Technologies
A new survey reveals that laboratories are planning to increase equipment purchases this year, with analytical instrumentation reported…